Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Investment to expand manufacturing and global medicine supply capacity
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Subscribe To Our Newsletter & Stay Updated
